CRP and psoriasis: In a post hoc analysis of pooled data from phase III/IV secukinumab studies in patients with psoriasis and PsA, reductions in inflammatory biomarker levels predictive of CVD and CVD-related mortality, C-reactive protein level, and neutrophil-to-lymphocyte ratio appeared as early as week 12 and were sustained over 52 weeks [41].